原發性高草酸尿症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2025 年，西班牙原發性高草酸尿症市場規模將達到 1,000 萬美元，到 2035 年將達到 2,200 萬美元。
• 推動市場成長的因素如下：
• RNA標靶療法和疾病修正治療。
• 提高基因檢測的準確性，達到早期診斷
• 未來的進展取決於能夠有效抑制草酸鹽生成並改善長期腎功能結果的治療方法。

原發性草酸尿症概述

原發性高草酸尿症是一種罕見的遺傳性疾病，其中1型最為常見。在疾病中，肝臟酵素功能障礙導致體內草酸鹽過度生成，引起疼痛難耐、反覆發作的腎結石和進行性性草酸鈣沉積。隨著時間的推移，這些病變會顯著損害腎功能，在晚期病例中，草酸鈣沉積也會擴散到腎臟以外的其他器官。傳統上，當出現腎衰竭時，治療選擇主要局限於同時進行肝腎移植。這是因為除了移植肝臟外，沒有其他方法可以糾正導致草酸鹽過度生成的根本酶異常。然而，隨著基於RNA干擾的療法的出現，情況發生了巨大變化。 RNA干擾療法旨在惰性參與草酸鹽生成的特定肝臟酵素。這種療法無需移植即可顯著降低草酸鹽水平，是基因靜默技術應用於常規臨床實踐（包括兒童）的最典型例子之一。目前已批准兩種療法，每種療法都針對生產途徑中的不同環節，醫生可以根據疾病亞型和腎功能選擇合適的治療方案。

主要亮點

• 根據預測，德國原發性高草酸尿症 (PH) 的確診病例數將從 2025 年的 168 例增加到 2035 年的 171 例。
• 原發性高草酸尿症是一種罕見的遺傳性代謝紊亂，其特徵是草酸鹽過度生成，導致反覆腎結石和進行性性腎損傷。
• 診斷延遲會導致不可逆的腎臟損傷和全身性併發症。
• 目前仍有大量未被滿足的治療需求，即能夠阻止疾病進展和維持腎功能的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Alnylam Pharmaceuticals
• YolTech Therapeutics Co., Ltd.
• Arbor Biotechnologies
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Primary Hyperoxaluria Market Outlook

Thelansis's "Primary Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Hyperoxaluria Overview

Primary hyperoxaluria is a rare inherited condition, most commonly its type 1 form, in which a malfunctioning liver enzyme causes the body to overproduce oxalate, leading to painful, recurrent kidney stones and progressive calcium oxalate deposits that can severely damage kidney function over time and, in advanced cases, spread beyond the kidneys to other organs. Historically, once kidney failure developed, treatment options were limited largely to combined liver and kidney transplantation, since replacing the liver was the only way to correct the underlying enzymatic defect driving oxalate overproduction. That changed with the arrival of RNA interference-based therapies designed to silence the specific liver enzymes responsible for oxalate production, offering a way to meaningfully lower oxalate levels without transplantation and marking one of the field's clearest examples of gene silencing technology translating into routine care, including in children. Two such therapies are now approved, each targeting a different point along the production pathway, giving physicians options depending on disease subtype and kidney function.

Key Highlights

• In Germany, diagnosed Primary Hyperoxaluria (PH) cases are projected to increase from 168 in 2025 to 171 by 2035.
• Primary Hyperoxaluria is a rare inherited metabolic disorder characterized by excessive oxalate production, leading to recurrent kidney stones and progressive renal damage.
• Delayed diagnosis can result in irreversible kidney dysfunction and systemic complications.
• Significant unmet need remains for therapies that prevent disease progression and preserve kidney function.

Market Overview

• The Spain Primary Hyperoxaluria market is projected to grow from $10M in 2025 to $22M by 2035.
• Market growth is driven by:
• Increasing adoption of RNA-targeted and disease-modifying therapies
• Improved genetic testing and earlier diagnosis
• Future growth will depend on therapies that effectively reduce oxalate production and improve long-term renal outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alnylam Pharmaceuticals
• YolTech Therapeutics Co., Ltd.
• Arbor Biotechnologies
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)